Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pathfinder Cell Therapy, Inc. (PFND)
Cambridge, MA, US
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -97.78% | -93.75% | -99.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+7.4% Q3'15: -20.0% (vs Q3'14)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'15: +63.3% (vs Q3'14)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q3'15: +0.0% (vs Q3'14)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.47× Q3'15: -6.51× (vs Q3'14)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chancellor LGT Asset Management, Inc. | 2.14M | 27.03% | 2.14M | — | 2.14M | — | BK, IA, HC | LGT Asset Management, Inc. - California | 1998-02-06 | ↗ |
| 2 | ###-##-####) | 155.0K | 5.29% | — | — | 155.0K | — | IN | United States of America | 1994-02-14 | ↗ |
| 3 | 04-2507163) | 155.0K | 5.29% | — | — | 155.0K | — | HC | Commonwealth of Massachusetts | 1994-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2008 | Robert P. Hickey President, CEO & CFO | 315.0K | — | — | 161.0K | 15.0K | 18.2K | 509.2K | 31.62% | ↗ |
| 2 | 2008 | Marc R. Sportsman Vice President of Sales | 248.4K | — | — | 110.0K | 18.8K | 17.6K | 394.8K | 27.87% | ↗ |
| 3 | 2008 | Eli Pines, Ph. D. Vice President and Chief Scientific Officer | 236.3K | — | — | 87.0K | 9.0K | — | 332.3K | 26.19% | ↗ |
| 4 | 2007 | Robert P. Hickey President, CEO & CFO | 300.0K | — | — | 340.0K | 75.0K | 14.1K | 729.1K | 46.63% | ↗ |
| 5 | 2007 | Eli Pines, Ph. D. Vice President and Chief Scientific Officer | 225.0K | — | — | 226.0K | 45.0K | 5.0K | 501.0K | 45.11% | ↗ |
| 6 | 2007 | Marc R. Sportsman Vice President of Sales | 160.0K | — | — | 66.0K | 45.0K | 12.0K | 283.0K | 23.32% | ↗ |
| 7 | 2006 | Robert P. Hickey President, CEO & CFO | 285.0K | — | — | 321.0K | 45.0K | 5.3K | 656.3K | 48.91% | ↗ |
| 8 | 2006 | Eli Pines, Ph. D. Vice President and Chief Scientific Officer | 212.0K | — | — | 227.0K | 25.0K | — | 464.0K | 48.92% | ↗ |
| 9 | 2000 | Robert P. Hickey Chairman, President and Chief Executive Officer | 217.6K | — | — | 415.3K | — | 2.0K | 635.0K | 65.41% | ↗ |
| 10 | 1999 | Robert P. Hickey Chairman, President and Chief Executive Officer | 219.7K | — | — | 169.4K | — | 1.9K | 391.0K | 43.33% | ↗ |
| 11 | 1998 | Robert P. Hickey Chairman, President and Chief Executive Officer | 229.2K | — | — | 420.0K | — | 1.8K | 651.0K | 64.51% | ↗ |
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard L. Franklin | Founder, Chief Executive Officer, President, Secretary & Executive Director | 120.0K | — |
| John Benson | Chief Financial Officer & Treasurer | 119.0K | male |
| Joerg Gruber | Founder & Chairman | 20.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PFND
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
